GlobeNewswire·Jul 17, 2026, 4:05 PM ET

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart held a virtual-only Annual Meeting of Stockholders on July 16, 2026, in South San Francisco, Calif.
Stockholders approved the election of six director nominees to serve until the 2027 Annual Meeting.
Stockholders ratified WithumSmith+Brown, PC as Vaxart's independent registered public accounting firm.
Stockholders rejected the advisory "say-on-pay" proposal regarding the compensation of named executive officers.
Final voting results will be reported on a Form 8-K filed with the U.S. Securities and Exchange Commission.
Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines that do not require refrigeration.
Current development programs include pill vaccines for coronavirus, norovirus, influenza, & a therapeutic vaccine for human papillomavirus (HPV).
Forward-looking statements highlight expectations for Phase 2b trial data analysis & complete study results anticipated in 2027.
The company holds broad patent applications covering its oral vaccination technology using adenovirus & TLR3 agonists.